Global Ustekinumab Market Size, Share and Trends Analysis Report, By Type (Intravenous and Subcutaneous), By Dosage Form (Capsule and Injection), By Application (Arthritis, Colitis, Lupus Erythematosus, Myositis Multiplex with Palmoplantar Pustulosis, Cirrhosis of the Liver, Diabetes, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2022-2028)

The global ustekinumab  market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ustekinumab is a monoclonal antibody medication used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The major factor expected to drive the market growth is the rising prevalence of psoriasis patients across the globe, changes in lifestyles, an increase in inclination toward smoking and alcohol, sedentary living, and unhealthy diets are making people prone to this condition (psoriasis).

Furthermore, a rise in awareness about the prevention and treatment of psoriasis and an increase in investments in R&D activities to develop a novel treatment for psoriasis will further propel the growth of the market during the forecast period. In addition, ustekinumab is used to treat Crohn’s disease and ulcerative colitis. This is a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever, where it works by stopping the action of the certain cells in the body that cause the symptoms of psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn’s disease.

Some major players in the market include Johnson & Johnson Services, Inc., Meiji Seika Pharma Co., Ltd., and Samsung Bioepis, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Lupin Inc. and Mylan a part of Viatris Inc. announced that they have launched the biosimilar etanercept Nepexto after receiving marketing authorization from the European Commission in May 2020 for indications, including psoriatic arthritis and plaque psoriasis.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Dosage Form
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape– Johnson & Johnson Services, Inc., Meiji Seika Pharma Co., Ltd., and Samsung Bioepis, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ustekinumab Market Report by Segment

By Type

• Intravenous
• Subcutaneous

By Dosage Form

• Capsule
• Injection

By Application

• Arthritis
• Colitis
• Lupus Erythematosus
• Myositis Multiplex with Palmoplantar Pustulosis
• Cirrhosis Of the Liver
• Diabetes
• Other

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Ustekinumab Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa